Open Access
Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
Marc Humbert,Richard Beasley,J. Ayres +2 more
- pp 425-434
About:
The article was published on 2017-01-01 and is currently open access. It has received 848 citations till now. The article focuses on the topics: Omalizumab.read more
Citations
More filters
Journal ArticleDOI
Effect of omalizumab on adenosine 5'-monophosphate responsiveness in subjects with allergic asthma.
TL;DR: Findings are consistent with the conclusion that the contribution of IgE to the development of AMP bronchoconstriction is more important than their role in the induction of methacholine hyperresponsiveness.
Journal ArticleDOI
Longitudinal increase in total IgE levels in patients with adult asthma: an association with poor asthma control
Akihiko Tanaka,Megumi Jinno,Kuniaki Hirai,Yoshito Miyata,Hiroko Mizuma,Munehiro Yamaguchi,Shin Ohta,Yoshio Watanabe,Mayumi Yamamoto,Shintaro Suzuki,Takuya Yokoe,Mitsuru Adachi,Hironori Sagara +12 more
TL;DR: Patients with increased IgE tended to have significantly higher mean age, more episodes of acute exacerbation within a year, lower ACT scores, and used oral corticosteroids more frequently than those with decreased or unchanged IgE.
Journal ArticleDOI
Omalizumab for severe allergic asthma in clinical trials and real-life studies: what we know and what we should address.
Marco Caminati,Gianenrico Senna,Massimo Guerriero,Anna Rita Dama,Fulvia Chieco-Bianchi,Giorgia Stefanizzi,Marcello Montagni,Erminia Ridolo +7 more
TL;DR: Though some similarities between RCTs and R-L studies strengthen omalizumab efficacy and safety outcomes, significant differences concerning study population features, follow-up duration, local adverse events and drop-out rate for treatment inefficacy emerge between the two study categories.
Journal ArticleDOI
The clinical profile of benralizumab in the management of severe eosinophilic asthma
TL;DR: The features of benralizumab compared with other anti-interleukin-5 biologics and omalizumAB, the identification of appropriate patients, the safety profile and future developments are discussed.
Journal ArticleDOI
Overlapping Effects of New Monoclonal Antibodies for Severe Asthma
TL;DR: The pathophysiology of some immunological aspects of severe asthma is presented, the adaptive and innate immunity arms as well as their interrelations are described, and the pharmacologic effects of these mAbs are outlined to clarify the overlapping effects of the different mAbs.
References
More filters
Journal ArticleDOI
Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials.
Elizabeth F. Juniper,Gordon H. Guyatt,Robert S. Epstein,Penelope J. Ferrie,Roman Jaeschke,T K Hiller +5 more
TL;DR: A questionnaire suitable for all adults with asthma and designed to be responsive to within subject change and therefore may be used as a measure of outcome in clinical trials in asthma is developed.
Allergy, rhinitis, other respiratory diseases Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
William W. Busse,Jonathan Corren,Bobby Q. Lanier,Margaret McAlary,Angel FowlerTaylor,Giovanni Della Cioppa,Niroo Gupta,Fort Worth +7 more
TL;DR: Omalizumab as discussed by the authors is a recombinant humanized anti-IgE mAb, which forms complexes with free IgE, blocking its interaction with mast cells and basophils.
Journal ArticleDOI
Proceedings of the ATS Workshop on Refractory Asthma Current Understanding, Recommendations, and Unanswered Questions
Sally E. Wenzel,John V. Fahy,Charles G. Irvin,Stephen P. Peters,Sheldon L. Spector,Stanley J. Szefler,Thomas B. Casale,Michelle M. Cloutier,Jack A. Elias,Mark C. Liu,Virginia Taggert +10 more
TL;DR: The proceedings of an American Thoracic Society (ATS)-sponsored workshop are hoped to serve as an aid to begin to define, understand, and manage these refractory patients.
Journal ArticleDOI
The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics
Markus Solèr,J. Matz,Robert G. Townley,R. Buhl,J. O'Brien,Howard Fox,J. Thirlwell,N. Gupta,G. Della Cioppa +8 more
TL;DR: Results indicate that omalizumab therapy safely improves asthma control in allergic asthmatics who remain symptomatic despite regular use of inhaled corticosteroids and simultaneous reduction in Corticosteroid requirement.